• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))
Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC wer...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: K Hannebicque, L Boulanger, E Bogart, S Giard, MP Chauvet, JL Houpeau Tags: Poster Session Abstracts Source Type: research

Update on Breast Cancer Risk Reduction Therapy
Abstract In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prol...
Source: Current Breast Cancer Reports - July 19, 2016 Category: Cancer & Oncology Source Type: research

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

1366p * risk-benefit index of tamoxifen and raloxifene for chemoprevention of korean breast cancer
Conclusions: Women under the age 40 had more benefit than risk from tamoxifen chemoprevention. In the postmenopausal women with a uterus, raloxifene has more favorable risk-benefit index than tamoxifen.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Chang, M. Tags: prevention and screening Source Type: research